白蛋白液体复苏对成人脓毒性休克死亡率的影响:随机试验的系统评价与双重频率学-贝叶斯Meta分析
该系统评价与双重频率学-贝叶斯Meta分析纳入7项随机对照试验(n=3273),比较白蛋白复苏策略与晶体液复苏在成人脓毒性休克中的效果。主要终点为最长随访期(至90天)全因死亡率,白蛋白组相对风险降低10%(RR 0.90,95%CI 0.83-0.99;p=0.02;I²=0%)。贝叶斯分析在主要弱信息先验下显示死亡率降低的后验概率为94.7%(P[RR<1.0])。预设亚组分析(白蛋白制剂、给药策略、试验水平基线血清白蛋白)未显示效应修饰证据。作者结论认为死亡率获益是可能的,但支持证据为间接且不精确(GRADE:低确定性),需要专门针对脓毒性休克白蛋白液体复苏的充分把握度试验。
要点
- 成人脓毒性休克中,白蛋白复苏策略与最长随访期全因死亡率相对风险降低10%相关(RR 0.90,95%CI 0.83-0.99;p=0.02;I²=0%)。
- 贝叶斯分析在主要弱信息先验下,死亡率降低的后验概率为94.7%(P[RR<1.0]),方向与频率学结果一致。
- 预设亚组分析(白蛋白制剂、给药策略、试验水平基线血清白蛋白)未显示效应修饰证据。
- 证据确定性为GRADE低,支持证据间接且不精确,作者认为需要专门针对脓毒性休克白蛋白复苏的充分把握度试验。
适用人群与场景
- 成人脓毒性休克患者;7项随机对照试验中3项主要纳入脓毒性休克患者,其余试验数据来自亚组或提取的分层数据。
研究设计与关键结果
- 系统评价与双重频率学-贝叶斯Meta分析纳入7项随机对照试验,共3273例成人脓毒性休克患者,比较白蛋白为基础复苏策略与晶体液为基础复苏。
- 主要终点为最长可用随访期(至90天)全因死亡率:白蛋白组相对风险降低10%(RR 0.90,95%CI 0.83-0.99;p=0.02;I²=0%)。
- 贝叶斯分析在主要弱信息先验下死亡率降低的后验概率为94.7%(P[RR<1.0])。
- 预设亚组分析(白蛋白制剂、给药策略、试验水平基线血清白蛋白)未显示效应修饰证据。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与双重频率学-贝叶斯Meta分析(遵循PRISMA指南,预注册方案CRD420261325998)。
- 证据等级:GRADE低确定性;作者结论认为死亡率获益是可能的,但支持证据间接且不精确。
- 局限:支持证据为间接且不精确(GRADE:低确定性);3项试验主要纳入脓毒性休克患者,其余数据来自亚组或提取的分层数据;作者认为需要专门针对脓毒性休克白蛋白液体复苏的充分把握度试验。
对床旁实践的改变
- 作者认为,在成人脓毒性休克中白蛋白复苏策略与最长随访期死亡率显著降低相关,但证据为GRADE低确定性且间接、不精确,需要专门针对脓毒性休克白蛋白液体复苏的充分把握度试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the effect of albumin-based fluid resuscitation on mortality in adults with septic shock.
DESIGN: Systematic review and dual frequentist-Bayesian meta-analysis of randomised clinical trials (RCTs), following PRISMA guidelines and preregistered protocol (CRD420261325998).
DATA SOURCES: PubMed, Embase, CENTRAL, and Scopus were searched from inception to February 2026.
METHODS: Eligible RCTs comparing albumin-based resuscitation strategies versus crystalloid-based resuscitation in adults with septic shock were included. The primary outcome was all-cause mortality at the longest available follow-up (up to 90 days). The analysis utilised random-effects models, subgroup analyses, and Bayesian methods.
RESULTS: Seven trials (n = 3273) were included. Three trials primarily recruited septic shock patients, while data from the remaining were derived from subgroups or extracted strata. At the longest available follow-up, albumin-based fluid resuscitation was associated with a statistically significant 10% reduction in the relative risk of all-cause mortality (RR 0.90, 95% CI 0.83-0.99; p = 0.02; I² = 0%). Bayesian analysis under the primary weakly informative prior yielded a posterior probability of mortality reduction of 94.7% (P[RR < 1.0]). Pre-specified subgroup analyses by albumin formulation, dosing strategy, and trial-level baseline serum albumin did not show evidence of effect modification.
CONCLUSION: In adults with septic shock, albumin-based resuscitation strategies are associated with a statistically significant reduction in mortality at the longest available follow-up, with a directionally concordant Bayesian estimate. A mortality benefit is therefore plausible, but the supporting evidence is indirect and imprecise (GRADE: low certainty). Adequately powered trials specifically addressing albumin fluid resuscitation in septic shock are warranted.
参考来源
- Mendes H, Wen HK, de Souza H, et al. Mortality effect of albumin fluid resuscitation in adults with septic shock: a systematic review and dual frequentist-bayesian meta-analysis of randomised trials. Crit Care. 2026. PMID: 42410446. doi:10.1186/s13054-026-06172-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。